ResearchAndMarkets.com released a comprehensive report covering over 1,350 precision medicine collaboration and licensing deals from 2019 to 2026. The report offers detailed insights into deal structures, financial terms, and partnership strategies, highlighting how data, diagnostics, and targeted therapies integrate in precision medicine. It serves as a key resource for companies to benchmark deals, prepare negotiations, and understand market standards with access to contract-level details. This transparency aids in valuing and structuring deals in a complex, data-driven therapeutic landscape.
Royalty Pharma reported a 6% increase in Portfolio Receipts to $773 million in Q2 2026, driven by a 14% rise in Royalty Receipts from key drugs like Tremfya and Evrysdi. The company acquired new royalty interests, including AstraZeneca’s cliramitug, ...
Pomerantz LLP is investigating AstraZeneca and some of its executives for potential securities fraud following the failure of the Phase-3 CARDIO-TTransform trial for Wainua, a treatment for amyloid cardiomyopathy. The trial did not meet its primary e...
SOPHiA GENETICS announced a multi-year collaboration with AstraZeneca to develop and commercialize two companion diagnostics supporting precision oncology therapies. The partnership will focus on creating decentralized diagnostics for solid tumors an...
The FTSE 100 fell 30 points to 10,838, dragged down by AstraZeneca's 9.3% drop following reports of merger talks with Bristol Myers Squibb, which raised concerns over strategic fit and antitrust issues. Commodity giants like Rio Tinto and BP also dec...
AIM ImmunoTech announced that the final patient has received their last dose in the Phase 2 DURIPANC trial testing Ampligen combined with AstraZeneca's Imfinzi for metastatic pancreatic cancer, ahead of schedule. The primary endpoint analysis will st...
